SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
BMRN Analysis & Videos »
BMRN: Bull or Bear?
FDA Calendar Updates: ABII, BMRN, JNJ, OSIP, Roche
BMRN
|
|
|
+20.36%
in
145 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 254 entries as of 7/13/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pendin...
|
UpDown Virtual Investing: Earn Real Money with Zero Risk
BMRN
|
|
|
-4.26%
in
231 days
(closed on 07/13/09)
<> 
<> The ultimate risk/reward trade for virtual investing – its is free and easy to register at the UpDown and users can earn real money at the site in two ways. The first is by beating the market (S&P 500 Index) on a monthly basis and the second is by referring investors. However, the referral system is designed to encourage legitamte referals only by basing the payment on how much the referred person earns on the site. So, if you refer someone who earns $100, you will receive 10% or $10 as a referral bo...
|
A New Index of Emerging Biotech & Pharma Companies
BMRN
|
|
|
+0.00%
in
24 hours
(closed on 11/23/08)
<> 
<>
The accompanying table includes the Top 40 rated companies in the ETF Innovators [ETFI] Emerging Bio-Pharma Index, which includes U.S.-listed companies with market caps between $150M-$1.5B and factors in each companies approved products, late-stage clinical pipeline, trailing 52-week stock price performance, and market cap weighting to calculate a stock rating.
The index has performed much better than its peers over the past year for both the Top 40 Rated (-9%) and all 76 companies (-15%) – doing bett< />< /><><>< />< /><>...
|
Bullish on BMRN ...
BMRN
|
|
|
-4.10%
in
401 days
BUSINESS SUMMARY BioMarin Pharmaceutical, Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. The company�s product portfolio comprises approved products and multiple investigational product candidates. Its approved products include Naglazyme (galsulfase), a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of genetic disease called mucopolysaccharidosis VI; Kuvan (sapropterin dihydrochloride), a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase i...
|
Biotech Blues: Four Stocks on Sale with Hope
BMRN
|
|
|
-11.33%
in
28 days
(closed on 11/22/08)
<> The following group of biotech companies have market caps of at least $300M with a one year stock price change that is below the iShares Nasdaq Biotech ETF (IBB) loss of 21.8% (Source: Google Finance, 10/25/08) with potential upside catalysts over the next year.
Alnylam Pharma (ALNY): $872M, -31.6%
Biogen Idec (BIIB): $12B, -48.4%
BioMarin Pharma (BMRN): $1.7B, -33%
Momenta Pharma (MNTA): $348M, -23.4%
Momenta and Novartis (NVS) expect to launch a generic version (M-Enoxaparin) of the injectable...
|
Who's Next in the Biotech Buyout Frenzy?
BMRN
|
|
|
-16.63%
in
12 days
(closed on 10/25/08)
<> The biotech industry is rapidly consolidating as big pharma companies put their cash stash to use in deals ranging from well-known large caps all the way down to unknown micro-caps in an effort to bolster their range of marketed products, late stage pipeline candidates, and drug discovery technology platforms.
Genentech (DNA) has rejected Roche's (RHHBY) $89 bid to acquire the remaining 44% of DNA it does not already own as insufficient. I think DNA could easily get $100 per share based on Eli Lilly's (LLY) $70 buyout of ImClo...
|
strong top-line growth and raised guidance
BMRN
|
|
|
-52.42%
in
582 days
BioMarin Pharmaceutical Inc. develops enzyme therapies for serious chronic genetic disorders and other diseases and conditions. Its leading product, Aldurazyme, is used for treating the ultra-rare genetic disorder mucopolysaccharidosis-I (MPS-I) while its second product, Naglazyme, is appoved for the treatment of MPS-VI. Recently, the company received FDA approval for its third product, Kuvan, for the treatment of PKU. Strong sales of Kuvan, coupled with accelerating sales of both Aludrazyme and Naglazyme, will drive the company to profitability in 2008 and beyond. As such, we maintain our ...
|
Kuvan sales...
BMRN
|
|
|
+2.64%
in
3 days
(closed on 01/25/08)
Biomarin has had a huge upturn do to FDA approval of Kuvan. Even with this higher price I still remain bearish. If insurance companies approve Kuvan, and if it succeeds in treatment of PKU. We should still see solid growth with the combination of solid sales of Naglazyme and Aldurazyme.
|
People Bullish on BMRN
People Bearish on BMRN
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on BMRN |
More Resources
|
About BioMarin Pharmaceutical Inc.
- Answers.com
